logo
Plus   Neg
Share
Email

BioXcel Expands Collaboration With Nektar To Initiate New Clinical Program

BioXcel Therapeutics, Inc. (BTAI) and Nektar Therapeutics (NKTR) announced they are expanding the ongoing research collaboration into a new clinical partnership. The collaboration will clinically evaluate the combination of BTI's BXCL701, a small molecule immune-modulator, DPP 8/9 and FAP inhibitor; Nektar's NKTR-214, a CD122-biased agonist; and a checkpoint inhibitor as a potential therapy for pancreatic cancer.

BTI will be responsible for initiating and managing the clinical program. The primary objectives of the study are to evaluate safety and efficacy of the triplet combination of BXCL701, NKTR-214 and a checkpoint inhibitor for the treatment of patients with unresectable or metastatic pancreatic cancer.

BTI and Nektar Therapeutics initially announced a preclinical research collaboration in November 2017.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Intel Corp. (INTC), the world's biggest chipmaker, Thursday said its profit and revenues for the fourth quarter trumped Wall Street estimates. The company's shares gained nearly 7 percent driven by strong outlook for the first quarter and full year 2020. Santa Clara, California-based Intel reported... ABH Pharma, Inc. and Stocknutra.com Inc. have recalled all of its dietary supplement products pursuant to a consent decree entered by the U.S. District Court for the Eastern District of New York. The companies have recalled all dietary supplement products manufactured and sold between January 2013... New York-based grocery chain Fairway Market has filed for Chapter 11 bankruptcy protection, but said its stores will remain open across the Tri-State area during the court process and it does not expect any service interruptions. This is the second time the company has filed for bankruptcy. The company earlier filed for Chapter 11 bankruptcy protection in 2016.
RELATED NEWS
Follow RTT
>